Ritter Pharmaceuticals (RTTR) Receiving Somewhat Positive Media Coverage, Study Finds

News stories about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.63726060255 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Several analysts have commented on the stock. ValuEngine upgraded shares of Ritter Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research lowered shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Ritter Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $13.75.

How to Become a New Pot Stock Millionaire

RTTR traded down $0.14 on Wednesday, hitting $2.73. The company had a trading volume of 39,878 shares, compared to its average volume of 87,183. Ritter Pharmaceuticals has a 52-week low of $1.80 and a 52-week high of $9.50. The firm has a market capitalization of $14.29, a PE ratio of -0.54 and a beta of 0.58.

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings data on Monday, March 19th. The biotechnology company reported ($1.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.60). analysts anticipate that Ritter Pharmaceuticals will post -2.8 earnings per share for the current fiscal year.

WARNING: “Ritter Pharmaceuticals (RTTR) Receiving Somewhat Positive Media Coverage, Study Finds” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/25/ritter-pharmaceuticals-rttr-receiving-somewhat-positive-media-coverage-study-finds.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply